Health Care & Life Sciences » Biotechnology | Cerenis Therapeutics Holding

Cerenis Therapeutics Holding S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
149.00
88.00
55.00
53.00
43.00
39
Gross Income
149.00
88.00
55.00
53.00
43.00
135
SG&A Expense
11,592.00
7,158.00
17,515.00
27,567.00
7,858.00
7,057
EBIT
11,741.00
7,246.00
17,570.00
27,620.00
7,901.00
6,922
Non Operating Income/Expense
29.00
115.00
341.00
170.00
1,719.00
24
Interest Expense
210.00
918.00
1,384.00
1,453.00
394.00
148
Pretax Income
9,633.00
7,777.00
18,734.00
28,461.00
6,240.00
7,457
Income Tax
1,891.00
1,214.00
2,096.00
3,590.00
1,262.00
1,152
Consolidated Net Income
7,742.00
6,563.00
16,638.00
24,871.00
4,978.00
6,305
Net Income
7,742.00
6,563.00
16,638.00
24,871.00
4,978.00
6,305
Net Income After Extraordinaries
7,742.00
6,563.00
16,638.00
24,871.00
4,978.00
6,305
Net Income Available to Common
7,742.00
6,563.00
16,638.00
24,871.00
4,978.00
6,305
EPS (Basic)
0.44
0.37
1.00
1.39
0.27
0.34
Basic Shares Outstanding
17,788.90
17,788.90
16,632.30
17,907.90
18,253.70
18,584.80
EPS (Diluted)
0.44
0.37
0.08
1.28
0.27
0.34
Diluted Shares Outstanding
17,788.90
17,788.90
206,544.10
19,391.30
18,253.70
18,584.80
EBITDA
11,592.00
7,158.00
17,515.00
27,567.00
7,858.00
6,883
Non-Operating Interest Income
2,347.00
502.00
561.00
442.00
336.00
206

About Cerenis Therapeutics Holding

View Profile
Address
33-43, av. Georges Pompidou- Bât. D2
Balma Midi-Pyrenees 31130
France
Employees -
Website http://www.cerenis.com
Updated 07/08/2019
Cerenis Therapeutics Holding SA is a biopharmaceutical company, which engages in development of high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. Its therapies consist of CER 001 and 209. The company was founded by Jean-Louis Dasseux on March 24, 2005 and is headquartered in Labege, France.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.